Open Access<p>New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties</p>
Author(s) -
Chung-Ping Yu,
Jennie GarciaOlivares,
Shawn A. Candler,
Stefan Schwabe,
Vladimir Maletic
Publication year - 2020
Publication title -
journal of experimental pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.555
H-Index - 12
ISSN - 1179-1454
DOI - 10.2147/jep.s256586
Subject(s) - serotonin , norepinephrine , action (physics) , 5 ht receptor , pharmacology , mechanism (biology) , mechanism of action , chemistry , medicine , neuroscience , endocrinology , psychology , dopamine , physics , receptor , biochemistry , quantum mechanics , in vitro
Viloxazine was historically described as a norepinephrine reuptake inhibitor (NRI). Since NRIs have previously demonstrated efficacy in attention deficit/hyperactivity disorder (ADHD), viloxazine underwent contemporary investigation in the treatment of ADHD. Its clinical and safety profile, however, was found to be distinct from other ADHD medications targeting norepinephrine reuptake. Considering the complexity of neuropsychiatric disorders, understanding the mechanism of action (MoA) is an important differentiating point between viloxazine and other ADHD medications and provides pharmacology-based rationale for physicians prescribing appropriate therapy.